Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Rating) CEO Jeremy Bender sold 12,500 shares of Day One Biopharmaceuticals stock in a transaction dated Tuesday, March 7th. The stock was sold at an average price of $20.01, for a total value of $250,125.00. Following the completion of the sale, the chief executive officer now directly owns 1,174,276 shares of the company's stock, valued at approximately $23,497,262.76. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Jeremy Bender also recently made the following trade(s):
Get Day One Biopharmaceuticals alerts:- On Thursday, February 16th, Jeremy Bender sold 3,022 shares of Day One Biopharmaceuticals stock. The stock was sold at an average price of $19.57, for a total value of $59,140.54.
- On Monday, January 23rd, Jeremy Bender sold 12,500 shares of Day One Biopharmaceuticals stock. The stock was sold at an average price of $22.00, for a total value of $275,000.00.
- On Wednesday, December 21st, Jeremy Bender sold 12,500 shares of Day One Biopharmaceuticals stock. The shares were sold at an average price of $20.32, for a total value of $254,000.00.
Day One Biopharmaceuticals Stock Performance
Shares of DAWN stock opened at $18.58 on Friday. Day One Biopharmaceuticals, Inc. has a fifty-two week low of $5.44 and a fifty-two week high of $28.35. The stock has a 50 day moving average price of $20.73 and a two-hundred day moving average price of $20.96. The company has a market capitalization of $1.37 billion, a P/E ratio of -8.56 and a beta of -1.94.
Institutional Trading of Day One Biopharmaceuticals
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Quantbot Technologies LP bought a new stake in Day One Biopharmaceuticals in the second quarter valued at approximately $51,000. UBS Group AG bought a new stake in Day One Biopharmaceuticals in the second quarter valued at approximately $69,000. Amalgamated Bank lifted its position in Day One Biopharmaceuticals by 21.0% in the third quarter. Amalgamated Bank now owns 3,577 shares of the company's stock valued at $72,000 after purchasing an additional 620 shares during the last quarter. California State Teachers Retirement System increased its stake in shares of Day One Biopharmaceuticals by 58.6% during the first quarter. California State Teachers Retirement System now owns 9,687 shares of the company's stock valued at $96,000 after buying an additional 3,581 shares during the period. Finally, American International Group Inc. increased its stake in shares of Day One Biopharmaceuticals by 92.7% during the first quarter. American International Group Inc. now owns 11,294 shares of the company's stock valued at $112,000 after buying an additional 5,434 shares during the period. Institutional investors own 86.08% of the company's stock.
Wall Street Analysts Forecast Growth
A number of research analysts have weighed in on the company. Capital One Financial assumed coverage on Day One Biopharmaceuticals in a report on Wednesday, February 8th. They set an "overweight" rating and a $40.00 target price for the company. Oppenheimer began coverage on Day One Biopharmaceuticals in a report on Thursday, February 2nd. They set a "market perform" rating for the company. Piper Sandler boosted their price objective on Day One Biopharmaceuticals from $40.00 to $45.00 and gave the stock an "overweight" rating in a report on Sunday, January 8th. HC Wainwright reissued a "buy" rating and set a $45.00 price objective on shares of Day One Biopharmaceuticals in a report on Tuesday. Finally, Needham & Company LLC reissued a "buy" rating and set a $48.00 price objective on shares of Day One Biopharmaceuticals in a report on Tuesday. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, Day One Biopharmaceuticals currently has a consensus rating of "Moderate Buy" and an average target price of $44.14.
Day One Biopharmaceuticals Company Profile
(Get Rating)
Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma.
Featured Stories
- Get a free copy of the StockNews.com research report on Day One Biopharmaceuticals (DAWN)
- Fossil Group: Should You Bet On Consumer Discretionary In 2023?
- BJ's Wholesale Club Stock Moves Higher After Strong Results
- Monthly Realty Income is About to Get Bigger
- 3 Large Cap Dividend Challengers for Millennial Investors
- Sea Ltd Is On The Verge Of A 100% Rally, Should You Buy?
Receive News & Ratings for Day One Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Day One Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.